{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:30:12Z","timestamp":1790206212581,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32MH109205"],"award-info":[{"award-number":["T32MH109205"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study investigates the association of clinical and demographic predictors with abdominal fat gain, measured using waist circumference (WC) and self-reported abdominal size.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data from ACTG A5257, a clinical trial that randomized treatment-na\u00efve HIV-infected participants to 1 of 3 antiretroviral regimens: raltegravir (RAL) or the protease inhibitors (PIs) atazanavir\/ritonavir (ATV\/r) or darunavir\/ritonavir (DRV\/r), each in combination with tenofovir disoproxil fumarate\/emtricitabine. Associations of treatment and baseline\/demographic characteristics with 96-week WC change were assessed using repeated-measures models. Ordinal logistic regression was used to examine the associations of predictors with week 96 self-reported abdominal changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population (n = 1809) was 76.0% male and predominantly black non-Hispanic (41.9%) and white non-Hispanic (34.1%). Mean baseline WC was 90.6 cm, with an average 96-week increase of 3.4 cm. WC increases were higher in the RAL arm compared with DRV\/r (P = .0130). Females experienced greater increases in WC on RAL vs ATV\/r than males (P = .0065). Similarly, a larger difference in WC change was found for RAL vs DRV\/r for black vs nonblack individuals (P = .0043). A separate multivariable model found that in addition to the treatment regimen, higher baseline viral load and lower CD4+ were also associated with WC increases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>With antiretroviral therapy initiation, higher WC increases in the RAL arm compared with PIs were more pronounced in female and black participants, and a more advanced baseline HIV disease state was a strong predictor of larger abdominal increases. Understanding factors predisposing individuals to abdominal fat gain could inform health management after therapy initiation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofy201","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:25:12Z","timestamp":1597047912000},"source":"Crossref","is-referenced-by-count":67,"title":["Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race"],"prefix":"10.1093","volume":"5","author":[{"given":"Priya","family":"Bhagwat","sequence":"first","affiliation":[{"name":"University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ighovwerha","family":"Ofotokun","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Department of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A","family":"McComsey","sequence":"additional","affiliation":[{"name":"Case Western University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd T","family":"Brown","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlee","family":"Moser","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A","family":"Sugar","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S","family":"Currier","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"2020081010564015700_CIT0001","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1590\/S0034-89102006000500012","article-title":"Central obesity and dietary intake in HIV\/AIDS patients","volume":"40","author":"Jaime","year":"2006","journal-title":"Rev Saude Publica"},{"key":"2020081010564015700_CIT0002","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/aid.2012.0214","article-title":"High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy","volume":"29","author":"Leclercq","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081010564015700_CIT0003","first-page":"3","article-title":"Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection","volume":"12","author":"Moyle","year":"2010","journal-title":"AIDS Rev"},{"key":"2020081010564015700_CIT0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/apc.2009.0191","article-title":"Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions","volume":"24","author":"Cabrero","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2020081010564015700_CIT0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/cir324","article-title":"Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s","volume":"53","author":"McComsey","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0006","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/cid\/ciu898","article-title":"Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial","volume":"60","author":"Martinez","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0007","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1093\/infdis\/jis205","article-title":"Body composition and metabolic changes in HIV-infected patients","volume":"205","author":"Stanley","year":"2012","journal-title":"J Infect Dis"},{"key":"2020081010564015700_CIT0008","first-page":"112","article-title":"Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy","volume":"14","author":"Domingo","year":"2012","journal-title":"AIDS Rev"},{"key":"2020081010564015700_CIT0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12170-013-0298-9","article-title":"Visceral adipose tissue and cardiovascular disease risk","volume":"7","author":"Hughes-Austin","year":"2013","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2020081010564015700_CIT0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/imj.12381","article-title":"Cardiovascular disease in human immunodeficiency virus","volume":"44","author":"Cheruvu","year":"2014","journal-title":"Intern Med J"},{"key":"2020081010564015700_CIT0011","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00392-012-0519-0","article-title":"Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study","volume":"102","author":"Esser","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"2020081010564015700_CIT0012","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIRCULATIONAHA.107.189624","article-title":"Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy","volume":"118","author":"Currier","year":"2008","journal-title":"Circulation"},{"key":"2020081010564015700_CIT0013","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/09540121.2010.543885","article-title":"Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study","volume":"23","author":"Lake","year":"2011","journal-title":"AIDS Care"},{"key":"2020081010564015700_CIT0014","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3945\/ajcn.112.047787","article-title":"Clinical utility of visceral adipose tissue for the identification of cardiometabolic risk in white and African American adults","volume":"97","author":"Katzmarzyk","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"2020081010564015700_CIT0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","article-title":"Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study","volume":"116","author":"Fox","year":"2007","journal-title":"Circulation"},{"key":"2020081010564015700_CIT0016","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e31814b94e2","article-title":"Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study","volume":"46","author":"Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081010564015700_CIT0017","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2009.06.011","article-title":"Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects","volume":"208","author":"Guaraldi","year":"2010","journal-title":"Atherosclerosis"},{"key":"2020081010564015700_CIT0018","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10554-011-9898-y","article-title":"Progression of coronary artery calcium in men affected by human immunodeficiency virus infection","volume":"28","author":"Guaraldi","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"2020081010564015700_CIT0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","article-title":"Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients","volume":"42","author":"Jemsek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1468-1293.2011.00941.x","article-title":"Randomized comparison of metabolic and renal effects of saquinavir\/r or atazanavir\/r plus tenofovir\/emtricitabine in treatment-na\u00efve HIV-1-infected patients","volume":"12","author":"Vrouenraets","year":"2011","journal-title":"HIV Med"},{"key":"2020081010564015700_CIT0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40261-014-0175-4","article-title":"Comparison of body composition changes between atazanavir\/ritonavir and lopinavir\/ritonavir each in combination with tenofovir\/emtricitabine in antiretroviral-na\u00efve patients with HIV-1 infection","volume":"34","author":"Moyle","year":"2014","journal-title":"Clin Drug Investig"},{"key":"2020081010564015700_CIT0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081010564015700_CIT0023","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","article-title":"Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK","volume":"53","author":"Rockstroh","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0024","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","article-title":"Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s","volume":"62","author":"McComsey","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0025","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/cid\/civ193","article-title":"Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257","volume":"60","author":"Ofotokun","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0026","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3851\/IMP3148","article-title":"Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes","volume":"22","author":"Bhagwat","year":"2017","journal-title":"Antivir Ther"},{"key":"2020081010564015700_CIT0027","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"A phase III comparative study of the efficacy and tolerability of three non-nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-na\u00efve HIV-1-infected volunteers: a randomized, controlled trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"2020081010564015700_CIT0028","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","article-title":"Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s","volume":"61","author":"Kelesidis","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0029","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwj111","article-title":"The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics","volume":"163","author":"Tien","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2020081010564015700_CIT0030","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597776","article-title":"Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with lamivudine and stavudine: a 96-week randomized, controlled study","volume":"48","author":"McComsey","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0031","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"2020081010564015700_CIT0032","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","article-title":"Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial","volume":"16","author":"Joly","year":"2002","journal-title":"AIDS"},{"key":"2020081010564015700_CIT0033","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1086\/430379","article-title":"Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women","volume":"40","author":"Jacobson","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0034","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1310\/hct1202-89","article-title":"Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada","volume":"12","author":"Andany","year":"2011","journal-title":"HIV Clin Trials"},{"key":"2020081010564015700_CIT0035","first-page":"72","article-title":"Sex and ethnic differences in validity of self-reported adult height, weight and body mass index","volume":"22","author":"Wen","year":"2012","journal-title":"Ethn Dis"},{"key":"2020081010564015700_CIT0036","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/eurpub\/ckp228","article-title":"Self-reported and measured weight, height and body mass index (BMI) in Italy, the Netherlands and North America","volume":"21","author":"Krul","year":"2011","journal-title":"Eur J Public Health"},{"key":"2020081010564015700_CIT0037","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpainsymman.2008.08.007","article-title":"Age and racial\/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy","volume":"38","author":"Silverberg","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"2020081010564015700_CIT0038","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1468-1293.2007.00537.x","article-title":"Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000\u20132006","volume":"9","author":"Nguyen","year":"2008","journal-title":"HIV Med"},{"key":"2020081010564015700_CIT0039","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1371\/journal.pmed.0030052","article-title":"Associations among race\/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy","volume":"3","author":"Foulkes","year":"2006","journal-title":"PLoS Med"},{"key":"2020081010564015700_CIT0040","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ajcn\/69.6.1162","article-title":"Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging","volume":"69","author":"Engelson","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"2020081010564015700_CIT0041","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"2020081010564015700_CIT0042","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","article-title":"Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy","volume":"34","author":"Sav\u00e8s","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020081010564015700_CIT0043","doi-asserted-by":"crossref","first-page":"e1005153","DOI":"10.1371\/journal.ppat.1005153","article-title":"Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection","volume":"11","author":"Damouche","year":"2015","journal-title":"PLoS Pathog"},{"key":"2020081010564015700_CIT0044","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fimmu.2014.00462","article-title":"Adipose-tissue and intestinal inflammation - visceral obesity and creeping fat","volume":"5","author":"Kredel","year":"2014","journal-title":"Front Immunol"},{"key":"2020081010564015700_CIT0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nut.2011.09.009","article-title":"Visceral fat and gut inflammation","volume":"28","author":"Drouet","year":"2012","journal-title":"Nutrition"},{"key":"2020081010564015700_CIT0046","doi-asserted-by":"crossref","first-page":"19033","DOI":"10.7448\/IAS.18.1.19033","article-title":"HIV\/AIDS and lipodystrophy: implications for clinical management in resource-limited settings","volume":"18","author":"Finkelstein","year":"2015","journal-title":"J Int AIDS Soc"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/11\/ofy201\/33629559\/ofy201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/11\/ofy201\/33629559\/ofy201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T15:01:41Z","timestamp":1597071701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy201\/5185211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy201","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,11,1]]},"article-number":"ofy201"}}